Equation (i) is of the form estimated by Scherer [17] , [18] , equation (ii) is of the form suggested by Hamburg [5] , equation (iii) is of the form suggested Grabowski [4] and equation (iv) is estimated by Scherer [17] .
Composite data were collected for six major pharmaceutical manufacturing companies which are representative of the entire pharmaceutical industry.* Loeb acknowledges research support from the Rutgers University Research Council. The authors arc grateful to V. Kerry Smith, Peter Asch, and an anonymous referee for their helpful comments.
'See Comanor [i], Grabowski [4] , Hamberg [5] , Scherer [17] , [18] , and Vernon and Gusen [21] . For an alternative view of the relationship between R & D and market structure see Phillips [10] , [11] and a review of that position in Kamicn and Schwartz [6] . Here technological innovation arising from exogenous science leads to concentration. As such, R & D affects market structure rather than vice versa. The pharmaceutical industry may prove an excellent case in point for the above suggested relationship.
* The data are provided in a recent report by Jesse J. Friedman and Associates [3] .
Various different measures of size were investigated in this study. They included: deflated net sales, deflated net income after taxes, and deflated pretax income. The basic format of the models suggested in equations (i) through (iv) was extended to investigate the effect of capital versus labor intensity on Research and Development. As such, all models were tested using either the capital/labor ratio or a transformation of it (e.g. As noted previously, four functional formats have been suggested for the evaluation of the Schumpeterian hypothesis in the pharmaceutical industry. The statistic R^ is generally used as the criterion for choosing among models. However, there are probletns associated with the use of this decision rule.* As such, we suggest supplementing the standard criteria of model selection {R'^, sufficiently large /-statistics, and coefficients with signs consistent with a priori theory) with a set of tests for specification errors suggested by Ramsey [12] , * See Dhrymes [2] . Also Ramsey and Gilbert [15] and Ramsey and Zarembka [i6] have shown that the R^ criterion may select a misspecified model as the appropriate one.
See Loeb [7] for an application of these tests to various investment functions.
The misspecification of a linear model will result in the violation of the full ideal conditions. Ramsey's tests investigate violation of these conditions via an analysis of the residual terms of the regression.
The tests: RESET and RASET are suggested for the detection of: omission of variables, misspeeification of the functional form, and simultaneous equation problems where the classical assumption of £'(/x)=o is violated. BAMSET-a Bartlett's M test for the non-equality of variances-is suggested for detecting heteroskedasticity, and WSET-the Shapiro-Wilk test-is suggested for detecting the presence of non-normality of the residuals.Î n that ordinary least squares residuals do not have a scalar covariance matrix even under full ideal conditions, the BLUS residuals (Best Linear Unbiased Scalars)-/i^-developed by Theil [ig] are employed in the tests suggested by Ramsey. These residuals, under full ideal conditions, fulfill the
It is assumed throughout the analysis that rejection of the null hypothesis: the full ideal conditions exist-stems from a specification error. Finally, the rejection of one or more of the Ramsey Tests is the decision rule for rejecting the null hypothesis.
EMPIRICAL RESULTS
As mentioned previously, the criteria for model selection are: high R^, significant /-statistics, coefficients which agree with a priori theory and failure to reject the full ideal conditions by the Ramsey Tests. Comparing models not rejected by the Ramsey Tests in terms of excluding versus including a (capital/ labor) variable indicated that the models omitting this regressor had higher R^ statistics. As such we eliminate such models from the possible alternatives investigated. ' Furthermore, in terms of our model selection criteria, we obtained superior results when we used deflated values of research and development outlays as our dependent variable instead of the index of average annual compensation of R & D scientists and engineers.
Tables I and II below present the final regressions considered as well as the Ramsey Tests. The f-statistic associated with each coefficient is to be found below each estimated parameter.• RESET is based on an ^-distribution, RASET on a /-distribution, and BAMSET on a chi-square distribution. ' Theil [20] has suggested the use of the criterion of maximum multiple correlation {R^) as the decision rule for choosing among models for the correct specification. Further, Dhrymes [2] has shown that one maximizes R^ by including regressors with (-values greater than unity and omitting those with (-values less than unity. The present study found the (-statistics associated with the (capita!/labor) regressors to be insignificant and/or less than unity.
* A 'runs' test was applied to the residuals of all the models to determine whether a serial correlation problem existed. The null hypothesis indicating that the residuals were randomly distributed failed to be rejected at the o-io level of significance for all models except model 7. From Table II we observe that 12 of the 18 models estimated were rejected by the Ramsey Tests. Many of these rejected models had high R^'s, indicating that R^ alone may prove to be a poor criterion for model selection. 
Applying the criteria of high R^ and significant coefficients to the models not rejected by the Ramsey Tests, we conclude that models 2 and 15 appear to be the best models, with model 2 having the higher 7?^^" It is of interest to note that both models are of similar form in that they both are polynomials of degree two with identical signs associated with the regressors.
For convenience, we choose model 2 as the proper specification in that it has the larger R'^ of tlie two models and in that model 2 is in terms of sales which is the common size variable in other studies.*Î t appears that the drug industry is characterized by decreasing returns to scale. As such, size is a causal factor in increases in R & D up to the point where given the equation:
» Due to scaling difficulties: S' was in terms of i x 10" deflated dollars; S^ was m terms of I X 10" deflated dollars; NYAT" was in terms of i x io^« deflated dollars; NYAT^ was in terms of i X 10'* deflated dollars; DPY^ was in terms of i X io'« deflated dollars; DPY' was m terms of i x 10" deflated dollars.
, , " " , u '" Note, however, that the dependent variables difler m the two models. Recall also tftat model selection by maximum R' as suggested by Theil [20] is based upon common regressands.
*' See, e.g. Grabowski [4] and Scherer [17] , [18] . The general results of this study compare favorably with the investigations by others,i5 where it was found that research intensity tends to diminish significantly as size increases in the drug industry. However, in this study a more rigorous procedure for model selection was undertaken based on a set of specification error tests. Finally, we were unable to find a statistically significant effect on R & D due to the 1962 Drug Amendments. RAMSEY TEST = Fail to reject the null hypothesis of no specification errors ihe assumption that the aggregate data are representative of the entire industrv is essential to our analysis. ' ** See Commanor [1] and Grabowski [4] .
